2000 HIV Human Functional Genomics Partnership Program (2000HIV)

Background Chronic HIV infection leads to a dysregulated immune system, even when full viral suppression is achieved. HIV causes persistent immune activation, relating to an array of common non-AIDS-related diseases such as cardiovascular disease (CVD) and non-alcoholic fatty liver disease (NAFLD). On the other hand, accelerated ageing of the immune system hinders effective immunity against infectious diseases and cancer. Likewise, this derailed inflammatory balance creates a niche for persistent viral replication and reservoir, and prevents cure or functional cure. Mechanisms behind this phenomenon are poorly understood. Inclusion of a larger cohort of HIV-infected patients allows for a more precise assessment of the factors underlying the immune dysregulation.

Primary Objectives

• Identify a set of candidate biomarkers that correlate with particular non-AIDS-related comorbidities
• Unravel biological processes associated with extreme HIV clinical phenotypes.
• Find therapeutic targets to identify novel assets or for repurposing of clinical phase assets from other disease areas for HIV.

Secondary Objectives

• Evaluate potential relationship of host/immune profiles on efficacy, safety, and tolerability of standard care regimens.

• Evaluate the contribution of age, sex, and genetics in host-immune profiles that are:

  • distinct to HIV infection relative to controls in other cohorts;
  • associated with non-AIDS-related comorbidities in HIV infection relative to non-HIV chronic disease.

Study design 2000 HIV patients will be included in the cohort. The investigators estimate a 2-year inclusion and 2-year follow-up period and will strive for the inclusion of several clinical phenotypes and classical risk group patients. Patients will be recruited from four Dutch HIV treatment centers.

At inclusion

1. Collection of metadata using questionnaires and patient medical records
2. Asses co-pathology (CVD and NAFLD)
3. Blood will be drawn for genetic, epigenetic, proteomic, metabolomic, microbiome, immunological, and virological analyses

After 2 years follow-up

1. Collection of metadata using questionnaires and patient medical records
2. Asses co-pathology (CVD and NAFLD)
3. Blood samples will be collected for biomarker and infection/inflammation parameter analysis

Study Overview

• Status: Completed
• Conditions: HIV Infections

Detailed Description

Study population A cohort with a total of 2000 HIV patients will be built, consisting of a discovery cohort (n=1200) and confirmation cohort (n=800). The investigators estimate a 2-year inclusion and 2-year follow-up period and will strive for the inclusion of several clinical phenotypes such as long-term non-progressors (~2-3%), immunologic non-responders (~3%), and rapid progressors (~4-5%) and classical risk group patients such as men who have sex with men (MSM), females, and subjects from Sub-Sahara Africa. Patients will be recruited from the following Dutch HIV Treatment Centers: Radboudumc (Nijmegen), Erasmus MC (Rotterdam), OLVG (Amsterdam), Elisabeth Twee-Steden Ziekenhuis (Tilburg).

A sample size calculation cannot be provided due to the variable frequencies of the various traits in genome-microbiome interaction, and their effect on cytokine production. Because of the explorative nature of this study, the size calculation will be variable depending on the type of polymorphism analyzed. The frequencies of the various microorganism classes in the colonizing microbiome is not known in our study population, and therefore power calculations are impossible to be performed.

Earlier studies in the Human Functional Genomics Project have assessed microbiome traits in 250-500 individuals. An earlier HFGP study included a uniform cohort of 200 HIV-infected individuals (all MSM). The present study will also include HIV-infected patients with a more extreme phenotype, females and subjects originating from Sub-Sahara Africa. Because of this, the investigators decided to increase the number of individuals tested to 2000, consisting of a discovery cohort of 1200 subjects, and a confirmation cohort of 800 participants.

Study visits and procedures At inclusion

1. The investigators will collect metadata using questionnaires on lifestyle, health and clinical symptoms, including neuropsychiatric symptoms. Relevant data will also be collected from the patients records in the medical centers and the HIV Monitoring Foundation.

2. Co-pathology will be assesed:

   • Cardiovascular risk scores (D:A:D risk score and Framingham CVD score) will be collected as well as ECG and intima-media thickness (IMT) measurements.
   • Non-Alcoholic Fatty Liver Disease (NAFLD) assessment through liver ultrasound and FibroScan.

3. Blood will be drawn (90 ml):

   • DNA will be isolated for genetic and epigenetic analysis.
   • The function of the immune system will be analyzed at several levels using circulating white blood cells from venous blood.
   • Metabolism and proteomics will be analyzed
   • Virological analysis, characterizing the HIV reservoir, HIV resistance and viral sequences in circulating DNA and RNA.
4. Microbiome analysis will be performed on stool and saliva samples.
5. Urine sample will be collected for creatinine measurements and microbiome.

After 2 years follow-up

1. The investigators will collect metadata using questionnaires on lifestyle, health and clinical symptoms, including neuropsychiatric symptoms. Relevant data will also be collected from the patients records in the medical centers and the HIV Monitoring Foundation.

2. Co-pathology will be assesed:

   • Cardiovascular risk scores (D:A:D risk score and Framingham CVD score) will be collected as well as ECG.
   • Non-Alcoholic Fatty Liver Disease (NAFLD) assessment through liver ultrasound and FibroScan.
3. Blood samples (10ml) will be collected for biomarker and infection/inflammation parameter analysis.

Patient informed consent procedure Patients will always be approached first by a treating physician or specialized nurse. They will be provided with information and will be asked if a physician-researcher may contact the patient. If there is oral consent for this, the researcher contacts the patient in one week to ask if they are interested in participating in the study. the physician-researcher will answer any questions the patient may have and plan the first visit. The informed consent procedure will be conducted during the patient's first visit.

Patient registry procedures All patient data will be recorded only in coded form in a secure database with audit and edit trail (CASTOR EDC). During the informed consent procedure, the patient is given a study code. The identifying patient data and study code is kept in a password-protected key file, only accessible to the local research team. No patient-identifying data will leave the local medical center.

In the questionnaires and eCRFs in CASTOR, the investigators will enter as many data checks as possible

Biomaterials All biomaterial (blood, stool, urine, saliva) will be transported to and processed in the laboratory of Experimental Internal Medicine of the Radboudumc in Nijmegen. Here, all the biomaterial will also be stored collectively. All materials will be handled and stored only under the patient's study code.

Monitoring Monitoring will be performed by an independent monitor according to the latest guidelines of the The Netherlands Federation of University Medical Centers. An initiation and close-out visit will be planned in plenary form with all the centers in Radboudumc. There will be one extra visit per center. During these visits informed consents will be checked, as well as inclusion and exclusion criteria and source data verification in a small subset of total participants.

Data collection for patient registry

Baseline data collected from electronic patient files or the HIV Monitoring Foundation during inclusion visit:

Medical history:

1. Inclusion date
2. Length and weight
3. Last known blood pressure (and date measured)
4. Seroconversion date (if known)
5. Date first HIV-positive test
6. Date start cART

7. HIV transmission risk behavior:

   • MSM
   • Heterosexual
   • Injecting drug use
   • Contaminated blood products
   • Unknown
8. First CD4 count
9. CD4 nadir
10. CD4/CD8 ratio pre-cART
11. HIV stadium at start cART according to CDC criteria
12. Pre-cART HIV RNA zenith

13. Opportunistic conditions before start cART

    • None
    • MTB
    • Fungal infections
    • Parasitic infections,
    • Bacterial infections

14. Malignancies before start cART

    • None
    • If yes, specify what kind, when and treatment

15. Other known medical problems before start cART, which require long-term treatment

    • None
    • If yes, specify what kind, when and treatment

16. Response cART:

    • Period between start cART and viral load < 500 (months)

    • Viral loads:

      • Undetectable after 24 weeks: yes/no
      • Number/frequency of residual viremia (positive test with signal <50 copies): last year and last 5 years
      • Number of viral blips (50-200): last year and last 5 years
      • Number of viremia: 200-1000: last year and last 5 years
      • Number of failing cART (>1000): last year and last 5 years
      • Resistance associated mutations pre-cART and following failure
      • CD4 reconstitution
      • CD4/CD8 ratio and normalization >1 yes/no after cART initiation
17. IRIS, yes/no

18. Opportunistic conditions after start cART (if known)

    • None
    • MTB
    • Fungal infections
    • Parasitic infections,
    • Bacterial infections

19. Malignancies after start cART (if known)

    • None
    • If yes, specify what kind, when and treatment

20. Vascular diseases after start cART:

    • None
    • Stroke/ TIA
    • Angina pectoris
    • Myocardial infarction
    • Claudicatio intermittens
    • Venous thrombo-embolism
    • Other …

21. SOAs

    • None
    • HAV: yes/no, if yes: treatment and how often

    • HBV:

      • Infected: active infection (PCR+) or non-active infection

      • Vaccination: No/Yes

        • Once with anti-HBs> 100
        • Two times vaccination leading to
    • anti-HBs> 100

    • anti-HBs< 100

      • No infection
    • HCV: yes/no, if yes: treatment and how often
    • Lues: yes/ no: if yes: treatment and how often
    • Chlamydia/Go: yes/ no: if yes: treatment and how often
    • HPV

22. COVID-19 infection before or after start cART:

    • Was a COVID-19 test done and if so type of test if known (PCR or antigen test), date of test and result of laboratory test for COVID-19 (positive or negative)
    • COVID-19 Serology results
    • Register COVID-19-related hospital admissions
    • COVID-19 vaccination: type and date(s)

    • Side effects of COVID-19 vaccination:

      • Mild: overall malaise, fatigue, muscle ache, pain at injection site, shivers, headache.
      • Moderate: mild symptoms to the extend (self)medication/pain relief is required.
      • Severe: fever >38.5 degrees Celsius and/or one or more days bedridden

23. cART regimes

    • Reasons for switching
24. Prescribed co-medication
25. Full current medication list

Physical examination

• Signs of Kaposi sarcoma
• Lymphadenopathy
• For determination of medication levels: when was the last date and time HIV-medication was taken?
• Other abnormalities: …

Cardiovascular risk profile:

• D:A:D (R) and Framingham scores
• ECG

Laboratory results of date closest to inclusion date (standard care at least once a year according to Dutch guidelines):

• Full blood count
• Liver enzymes (ALAT, AF, bilirubin)
• Creatinine
• HIV-RNA
• CD4 and CD8 counts
• Glucose
• Lipid profile
• TPHA/VDRL

• HCV serology (for all at risk, such as MSM and i.v. drug users)

  • If positive, HCV PCR
• HPV diagnostics in females (PAP, PCR)
• Urine diagnostics (if available): α1-microglobulin, protein, albumin, phosphate, creatinin

Baseline data collected from electronic patient files or the HIV Monitoring Foundation during 2-year follow-up visit:

Medical history last 2 years:

1. Date of 2 year follow-up visit
2. Weight
3. Last known blood pressure (and date measured)

4. Response cART last 2 years

   • Number of residual viremia: last 2 years
   • Number of viral blips (20-200): last 2 years
   • Number of viremia (200-1000): last 2 years
   • Number of failing cART (>1000): last 2 years
   • CD4 count
   • CD4/CD8 ratio (if known)

5. Opportunistic conditions last 2 years

   • None
   • MTB
   • Fungal infections
   • Parasitic infections,
   • Bacterial infections

6. Malignancies in the last 2 years

   • None
   • If yes, specify what kind, when and treatment

7. Signs/symptoms of cardiovascular diseases in the last 2 years:

   • None
   • Stroke/ TIA
   • Angina pectoris
   • Myocardial infarction
   • Claudicatio intermittens
   • Venous thrombo-embolism
   • Other …

8. New SOAs in the last 2 years

   • HAV: yes/no, if yes: treatment and how often

   • HBV:

     • Infected: active infection (PCR+), non-active infection,

     • Vaccination: No/Yes

       • Once with anti-HBs> 100
       • Two times vaccination leading to
   • anti-HBs> 100

   • anti-HBs< 100

     • No infection
   • HCV: yes/no, if yes: treatment and how often
   • Lues: yes/ no: if yes: treatment and how often
   • Chlamydia/Go: yes/ no: if yes: treatment and how often

9. COVID-19 infection before or after start cART:

   • Was a COVID-19 test done and if so type of test if known (PCR or antigen test), date of test and result of laboratory test for COVID-19 (positive or negative)
   • COVID-19 Serology results
   • Register COVID-19-related hospital admissions
   • COVID-19 vaccination: type and date(s)

   • Side effects of COVID-19 vaccination:

     • Mild: overall malaise, fatigue, muscle ache, pain at injection site, shivers, headache.
     • Moderate: mild symptoms to the extend (self)medication/pain relief is required.
     • Severe: fever >38.5 degrees Celsius and/or one or more days bedridden

10. cART regimes in the last 2 years

    • Reasons for switching available from 'Stichting HIV Monitoring'
11. Prescribed co-medication
12. Full current medication list

Physical examination

• Signs of Kaposi sarcoma
• Lymphadenopathy
• For determination of medication levels: when was the last date and time HIV-medication was taken?
• Other abnormalities: …

Cardiovascular risk profile:

• D:A:D (R) and Framingham scores
• ECG

Laboratory results of date closest to follow-up visit date:

• Full blood count
• Liver enzymes (ALAT, AF, bilirubin)
• Creatinine
• HIV-RNA
• CD4 and CD8 counts
• Glucose
• Lipid profile
• TPHA/VDRL

• HCV serology

  o If positive, HCV PCR

• HPV diagnostics in females (PAP, PCR)
• Urine diagnostics

• Study Type: Observational
• Enrollment (Actual): 1910

Contacts and Locations

Study Locations

• Netherlands
  • Amsterdam, Netherlands, 1091AC
    • Onze Lieve Vrouwe Gasthuis
  • Nijmegen, Netherlands, 6525GA
    • Radboudumc
  • Rotterdam, Netherlands, 3015GD
    • Erasmus MC
  • Tilburg, Netherlands, 5042AD
    • Elisabeth Twee-Steden ziekenhuis

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

HIV-infected patients (n=2000) will be recruited from the following Dutch HIV Treatment Centres: Radboudumc (Nijmegen), ErasmusMC (Rotterdam), Onze Lieve Vrouwe Gasthuis (Amsterdam), Elisabeth-TweeSteden Ziekenhuis (Tilburg). Our aim is to include approximately 20% females, 20% of Sub-Sahara African origin, elite controllers (~2-3%), immunologic non-responders (~3%), and rapid progressors (~4-5%) The total number of adult HIV patients under care in these treatment centers is 7000, of which 80% is male and 70% is of Caucasian origin. There is wide age distribution among the adult HIV population.

Description

Inclusion Criteria:

• HIV-infected,
• aged ≥18 years,
• on cART ≥6 months with an HIV-RNA load <200 copies/mL, *Apart from the above-mentioned subjects, elite controllers that are not on cART, are also eligible.

Exclusion Criteria:

• No informed consent
• Insufficient communication because of language or other problems
• Active hepatitis B/C or signs of acute infections
• Pregnancy

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in liver fibrosis	Change in liver fibrosis measurement by FibroScan (method by Echosens)	Change: 2-year value - baseline value
Change in liver steatosis	Change in liver steatosis measurement by FibroScan (method by Echosens) and liver ultrasound (method developed by Radboudumc)	Change: 2-year value - baseline value
Change in cardiovascular risk score (Framingham score)	Framingham score	Change: 2-year value - baseline value
Change in cardiovascular risk score (D:A:D score)	D:A:D score	Change: 2-year value - baseline value
Number and type of cardiovascular events	Recoring of cadiovascular diseases from patient file: Stroke/ TIA; Angina pectoris; Myocardial infarction; Claudicatio intermittens; Venous thrombo-embolism; Other …	Number of events over 2 years between baseline and 2-year time point
Genetic data	Genome-wide genotype data including >8 million SNPs per individual	At baseline only
Colonizing microbiome profile	Colonizing microbiome profile will be generated from stool and saliva samples	At baseline only
Transcriptomics	RNA-sequencing will be performed in PBMCs	At baseline only
Quantification of a wide range of metabolites	Metabolomics analysis by multiplex immunoassays will be performed in plasma or serum	At baseline only
Cytokine production of PBMCs in ex vivo stimulation experiments	Ex vivo cytokine responses of isolated PBMCs to a range of stimuli (TLR ligands, killed pathogens and viral antigen stimuli)	At baseline only
Immune phenotyping	Extensive phenotyping of circulating immune cells by flow cytometry analysis	At baseline only
Change in ECG	Standardized signs of myocardial infarction with MEANS ECG software, as extensively described elsewehere. In addition, we will look at the full list of ECG output measurements as described elsewhere*: in brief, MEANS reliably provides output on interpretation of the ECG rhythm and morphology. The morphological interpretation consists of separate analyses of the P wave, QRS complex, and ST-T segment. Reference: Van den Berg ME, Rijnbeek PR, Niemeijer MN, et al. Normal values of corrected heart-rate variability in 10-second electrocardiograms for all ages. Front Physiol. 2018;9:424	ECG paramater changes between baseline and 2-year time visit
Intima-media thickness	Ultrasound measurement of intima-media thickness in the carotid artery as a measure for atherosclerosis and cardiovasculr disease risk.	At baseline only

Collaborators and Investigators

• Sponsor: Radboud University Medical Center
• Collaborators: Erasmus Medical Center; ViiV Healthcare; Elisabeth-TweeSteden Ziekenhuis; Onze Lieve Vrouwe Gasthuis
• Investigators: Principal Investigator: Quirijn de Mast, Dr., Radboud university medical center; Principal Investigator: Annelies Verbon, Prof., Erasmus Medical Center; Principal Investigator: Willem Blok, Dr., Onze Lieve Vrouwe Gasthuis; Principal Investigator: Marvin Berrevoets, Drs., Elisabeth Twee-Steden ziekenhuis

Study record dates

Study Major Dates

• Study Start (Actual): October 16, 2019
• Primary Completion (Actual): July 27, 2023
• Study Completion (Actual): July 28, 2023

Study Registration Dates

• First Submitted: May 22, 2019
• First Submitted That Met QC Criteria: June 19, 2019
• First Posted (Actual): June 21, 2019

Study Record Updates

• Last Update Posted (Actual): December 8, 2023
• Last Update Submitted That Met QC Criteria: December 7, 2023
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Keywords: Cardiovascular disease; Inflammation; HIV; Non-alcoholic fatty liver disease; Omics data
• Additional Relevant MeSH Terms: RNA Virus Infections; Virus Diseases; Infections; Blood-Borne Infections; Communicable Diseases; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; Immunologic Deficiency Syndromes; Immune System Diseases; Urogenital Diseases; Genital Diseases; HIV Infections
• Other Study ID Numbers: NL.68056.091.18

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No